Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity ; volume:20 ; number:1 ; day:7 ; month:10 ; year:2020 ; pages:1-13 ; date:12.2020
Cancer cell international ; 20, Heft 1 (7.10.2020), 1-13, 12.2020
- Urheber
-
Zhu, Jialin
Wang, Yan
Li, Dai
Zhang, Haonan
Guo, Zhi
Yang, Xueling
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-020-01583-3
- URN
-
urn:nbn:de:101:1-2020112220245693910102
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:19 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhu, Jialin
- Wang, Yan
- Li, Dai
- Zhang, Haonan
- Guo, Zhi
- Yang, Xueling
- SpringerLink (Online service)
Ähnliche Objekte (12)
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
P60. Microtubule-depolymerising agents used in antibody-drug-conjugates induce anti-tumour immunity by stimulation of dendritic cells
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
P60. Microtubule-depolymerising agents used in antibody-drug-conjugates induce anti-tumour immunity by stimulation of dendritic cells
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
An anti-CD30 immunocytokine with combined IL-2 and IL-12 domains enhances anti-tumour immunity
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response